Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

FLCCC Alliance Convenes Global Panel That Warns World Governments of the Consequences of Not Deploying Ivermectin for COVID-19

Panel Calls for Ivermectin's Immediate Global Adoption to End the Pandemic.


News provided by

FLCCC

Mar 18, 2021, 21:45 ET

Share this article

Share toX

Share this article

Share toX

The Global Expert Panel convened by the FLCCC Alliance on March 18, 2021
The Global Expert Panel convened by the FLCCC Alliance on March 18, 2021

WASHINGTON, March 18, 2021 /PRNewswire-PRWeb/ -- A group of medical and scientific experts convened by the Front Line COVID-19 Critical Care Alliance (FLCCC) today call for action to put an end to the COVID-19 pandemic by immediately adopting policies that allow for the use of ivermectin in the prevention and treatment of COVID-19.

Scientists and physicians from the U.S., U.K., E.U., South America, and Israel gathered to discuss the latest data on how ivermectin has reduced positive COVID-19 cases in major cities across the world, ivermectin's role in the early treatment of COVID-19, and why ivermectin needs to be adopted as safe and effective prevention and treatment of COVID-19.

Why wait? The drug is very safe, and it could crush the pandemic in a few weeks. It is beyond absurd to delay its use and ask for even more data," said Marc Wathelet, Ph.D.

Post this

"Ivermectin is safer than most medicines being given (for Covid), meta-analyses of mountains of data show that it reduces mortality 68%," said Tess Lawrie, Director, The Evidence-Based Medicine Consultancy Ltd. and expert consultant to the WHO, United Kingdom. "For a government to continue not to take action on ivermectin is to let people suffer from this terrible disease."

The panelists' discussion included the latest results from trials in several regions, including Brazil, where ivermectin is used to prevent COVID-19 in regions where researchers see far fewer COVID-19 cases and no presence of any COVID-19 variants compared to areas where ivermectin is not widely used. "We are seeing fewer hospitalizations, faster recovery and no presence of disease from the variants in these regions," said Hector Carvallo, MD, Professor of Medicine, Adolfo Ibanez University y Universidad Mayor, Argentina.

The experts also discussed the extensive body of science showing ivermectin as a safe and effective preventative and treatment for COVID-19. "Why wait? The drug is very safe, and it could crush the pandemic in a few weeks. It is beyond absurd to delay its use and ask for even more data," said Marc Wathelet, Ph.D., Molecular and cellular biologist, Coronavirus specialist from Belgium. "I have questions about the ethics of conducting more RCTs (randomized clinical trials). These studies will include people who we know will get sicker without ivermectin."

A recording of the panel discussion will premiere live on Friday, March 19 at 7 pm E.T. on the FLCCC YouTube Channel. FLCCC president and chief medical officer Pierre Kory, MD, MPA will answer viewer questions in the live chat. To join the premiere and live event with Dr. Kory and see the latest updates from FLCCC, use the following link to subscribe:
https://www.youtube.com/channel/UC5rJlf5jdr_I6qiozbQdx-g

Medical Expert Panelists:

  • Pierre Kory, M.P.A, MD, President and Chief Medical Officer, FLCCC

    -Former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin

  • Prof. Eli Schwartz, MD, DTMH, The Center for Geographic Medicine and Tropical Diseases, The Chaim Sheba Medical Center, Israel

    -Recognized center by the Ministry of Health of Israel for tropical and travel diseases.

  • Tess Lawrie, MBBCh, PhD, Director, The Evidence-Based Medicine Consultancy Ltd., United Kingdom

    -Recently completed meta-analysis of Ivermectin for the treatment of COVID-19
    -Expert consultant to the WHO

  • Hector Carvallo, MD, Professor of Medicine, Adolfo Ibanez University y Universidad Mayor

    -Former Director Ezeiza Public Hospital, Argentina

  • Marc Wathelet, PhD, Molecular and cellular biologist, Coronavirus specialist, Belgium

    -Specializes in the study of respiratory viruses.
    -Has led several research projects into different strains of coronavirus, including SARS-CoV2, which caused the epidemic of severe acute respiratory syndrome in 2003-2004.

About the Front Line COVID-19 Critical Care Alliance
The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned Critical Care physician/scholars – with the academic support of allied physicians from around the world – to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol – introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19. Now, the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released – and is a potential solution to the global pandemic.
For more information: https://covid19criticalcare.com/

###

Media Contact

Joyce Kamen, [email protected], +1 513-486-4696, [email protected]

SOURCE FLCCC

Related Links

http://www.flccc.net

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.